The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting. IPI targets CTLA-4, blocking its immune inhibition and thus enhancing T cell-mediated malignant cell cytotoxicity. The addition of DAC was intended to increase this action and the results from the study showed encouraging response rates in both arms. Immune-related adverse events were frequent in both arms but similar to prior data. The activity of the combination therapy, specifically for transplant-naïve individuals, indicates that an alloreactive environment is not necessary for CTLA-4 blockade success with IPI. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Jacqueline Garcia, MD, has received institutional/trial support from Eli Lily, Pfizer, Genentech and AbbVie, and is on the scientific advisory board for AbbVie.
